Recent Advance in Drug Development of Squamous Cell Carcinoma
- 作者: Lei J.1, Fu B.1, Yin H.1, Tang G.1, Zhu S.1, Yan C.1, He Q.1
-
隶属关系:
- ,
- 期: 卷 15, 编号 7 (2015)
- 页面: 816-827
- 栏目: Oncology
- URL: https://kld-journal.fedlab.ru/1871-5206/article/view/695264
- DOI: https://doi.org/10.2174/1871520615666150113103938
- ID: 695264
如何引用文章
全文:
详细
Squamous cell carcinoma (SCC) has a high worldwide incidence that is commonly seen as head and neck cancers, esophageal cancers, and non-small cell lung cancers. There is a poor prognosis for SCC due to potential recurrence and its metastatic tendency so the 5-year survival rate is very low. Target therapy is a novel and promising treatment strategy exhibiting great anti-tumor effects and survival benefits in SCC. This review summarizes current treatment strategies from clinical and experimental studies, including the agents targeting epidermal growth factor receptors, RNA polymerase, toll-like receptors, p38α MAPK, CXCR, and the related combination therapy regimens. However, there are still many challenges we have to face. It is a burning need to improve the development and availability of drug formulations.
作者简介
Jun Lei
,
Email: info@benthamscience.net
Bing Fu
,
Email: info@benthamscience.net
Hang Yin
,
Email: info@benthamscience.net
Guanxiu Tang
,
Email: info@benthamscience.net
Shujuan Zhu
,
Email: info@benthamscience.net
Chunli Yan
,
Email: info@benthamscience.net
Quanyong He
,
Email: info@benthamscience.net
补充文件
